2023
Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies
Patel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, Fathi A, Kuykendall A, Zheng F, Walker C, Cheng L, Marando C, Savona M. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies. Clinical Lymphoma Myeloma & Leukemia 2023, 23: 674-686. PMID: 37290996, DOI: 10.1016/j.clml.2023.05.002.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsDose-limiting toxicityAdvanced hematologic malignanciesAcute myeloid leukemiaMyelodysplastic syndromeHematologic malignanciesCare agentsHigh-risk myelodysplastic syndromeMDS/myeloproliferative neoplasmPhase 1/2 studyEffective combination strategiesAdverse eventsComplete responseLymphoproliferative neoplasmsWeek 12Multiple myelomaSpleen volumeAcute leukemiaMyeloid leukemiaPreclinical modelsPatientsMyeloproliferative neoplasmsMoloney murine leukemia virus (PIM) kinasesMyelofibrosisKinase inhibitors
2020
Older Adults without Desired Surrogates in a Nationally Representative Sample
Cohen AB, Costello DM, OʼLeary JR, Fried TR. Older Adults without Desired Surrogates in a Nationally Representative Sample. Journal Of The American Geriatrics Society 2020, 69: 114-121. PMID: 32898285, PMCID: PMC7854949, DOI: 10.1111/jgs.16813.Peer-Reviewed Original ResearchConceptsNuclear familiesOlder adultsNational Social LifeNationally Representative SampleSocial lifeCommunity-dwelling older adultsRepresentative sampleSocial connectednessCross-sectional studyHealth care agentCare agentsCognitive impairmentLogistic regressionLow indicatorsAdultsRespondentsConfidantsIntact capacityMedical decisions
2017
Medical marijuana in pediatric oncology: A review of the evidence and implications for practice
Ananth P, Reed‐Weston A, Wolfe J. Medical marijuana in pediatric oncology: A review of the evidence and implications for practice. Pediatric Blood & Cancer 2017, 65 PMID: 28926679, DOI: 10.1002/pbc.26826.Peer-Reviewed Original ResearchConceptsMedical marijuanaPediatric oncologyCancer-related symptomsPediatric oncology patientsSupportive care agentsMechanism of actionSupportive carePediatric patientsOncology patientsSerious illnessCare agentsPatientsOncologyMarijuanaPotential benefitsPurported benefitsFuture investigationsReviewSymptomsIllnessCancerCare
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply